ArticlePhysics in medicine and biology2017
Tracking short-term biodistribution and long-term clearance of SPIO tracers in magnetic particle imaging.
Article in Physics in medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Sensitivity and Cellular Labelling Performance of Magnetically Fractionated SPIONs for Multimodal MRI/MPI Imaging.Nanomaterials (Basel, Switzerland) · 2026Article
- From Magnetic Moment to Magnetic Particle Imaging: A Comprehensive Review on MPI Technology, Tracer Design and Biological Applications.Pharmaceutics · 2026Review
- Magnetic Particle Imaging in Human Subjects.Research square · 2026Article
- Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models.Theranostics · 2026Article
- On the effect of reference and sample volume on magnetic particle imaging quantification.Journal of magnetism and magnetic materials · 2025Article
- Stimuli-Responsive Materials for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Biotransformation and biological fate of magnetic iron oxide nanoparticles for biomedical research and clinical applications.Nanoscale advances · 2025Review
- On the partial volume effect in magnetic particle imaging.Physics in medicine and biology · 2025Article
- Advances in engineering nanoparticles for magnetic particle imaging (MPI).Science advances · 2025Review
- Pharmacokinetic Profiling of Unlabeled Magnetic Nanoparticles Using Magnetic Particle Imaging as a Novel Cold Tracer Assay.Nano letters · 2024Article
- Article
- Engineered SPIONs functionalized with endothelin a receptor antagonist ameliorate liver fibrosis by inhibiting hepatic stellate cell activation.Bioactive materials · 2024Article
- Advances in Vascular Diagnostics using Magnetic Particle Imaging (MPI) for Blood Circulation Assessment.Advanced healthcare materials · 2024Review
- Elucidating Iron Metabolism through Molecular Imaging.Current issues in molecular biology · 2024Review
- High-efficiency magnetophoretic labelling of adoptively-transferred T cells for longitudinalTheranostics · 2024Article
- Article
- Progress in magnetic particle imaging signal and iron quantification methodsNanoscale advances · 2023Article
- Functional magnetic particle imaging (fMPI) of cerebrovascular changes in the rat brain during hypercapnia.Physics in medicine and biology · 2023Article
- Article
- Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications.Journal of nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Magnetic particle imaging (MPI) is an emerging tracer-based medical imaging modality that images non-radioactive, kidney-safe superparamagnetic iron oxide (SPIO) tracers. MPI offers quantitative, high-contrast and high-SNR images, so MPI has exceptional promise for applications such as cell tracking, angiography, brain perfusion, cancer detection, traumatic brain injury and pulmonary imaging. In assessing MPI's utility for applications mentioned above, it is important to be able to assess tracer short-term biodistribution as well as long-term clearance from the body. Here, we describe the biodistribution and clearance for two commonly used tracers in MPI: Ferucarbotran (Meito Sangyo Co., Japan) and LS-oo8 (LodeSpin Labs, Seattle, WA). We successfully demonstrate that 3D MPI is able to quantitatively assess short-term biodistribution, as well as long-term tracking and clearance of these tracers in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.